Genelux opened at $1.88, in line with its previous close of $1.88. In the last trading session, the stock traded between $1.81 and $1.95. It showed an upward intraday trend.
Return calculator
Time Period
An investment of $100 made 4 years ago in Genelux is now worth
$ 30.94
Resulting in a loss of
$ 69.06 (69.06%)
Invest with $1
Note: Past profits do not guarantee future returns.
Analyst Overview
Rating from 3 Analysts
Buy
100%
Hold
0%
Sell
0%
Markets Today
Today's Change
+$0.02 (+1.22%)
Day High
$1.95
Day Low
$1.81
Day Open
$1.88
Prev Close
$1.88
Volume
1,12,556
1W Return
-2.31%
1M Return
-25.23%
3M Return
-28.43%
6M Return
-34.38%
1Y Return
-68.18%
Fundamentals
Market Cap ($ Mn)
86
PE Ratio
-
PB Ratio
7.45
PEG Ratio
-
ROE
-145.91%
ROCE
-141.90%
EPS (TTM)
$-0.21
Investment Returns
1 Week
-2.31%
1 Month
-25.23%
3 Months
-28.43%
6 Months
-34.38%
9 Months
-21.36%
Financials
Quarterly
All values in $ Mn
0.0
Dec 24
0.0
Mar 25
0.0
Jun 25
0.0
Sep 25
0.0
Dec 25
0.0
Jun 26
Updates
14Aug
Genelux Q2 net loss widens to $9.5 million, misses EPS estimate
Genelux Corporation posted a Q2 2026 net loss of $9.5 million, missing the consensus EPS estimate of $(0.19) with an actual of $(0.21). R&D costs rose to $6.5 million due to Phase 3 trials, while cash reserves stood at $18.7 million.
3mo ago
30Jun
Genelux publishes VIRO-15 trial findings on ovarian cancer
Genelux Corporation published findings from the Phase 1b/2 VIRO-15 trial, showing Olvi-Vec-primed immunochemotherapy modulates the tumor microenvironment and activates the immune system in platinum-resistant ovarian cancer patients. The study, published in Gynecologic Oncology Reports, supports the reversal of platinum resistance and identifies gene expression changes linked to improved prognosis.
